



ELSEVIER

The Brazilian Journal of INFECTIOUS DISEASES

www.elsevier.com/locate/bjid


Original article

Hematological particularities and co-infections in injected drug users with AIDS

Denise Menezes Brunetta^{a,*}, Gil Cunha De Santis^a, Fernando Crivelenti Vilar^b,
Renata Amorim Brandão^c, Renata Zomer de Albernaz Muniz^b,
Geovana Momo Nogueira de Lima^b, Manuela Emiliana Amorelli-Chacel^b,
Dimas Tadeu Covas^{a,c}, Alcyone Artioli Machado^b

^a Center for Cell Based Therapy, Medical School of Ribeirão Preto, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil

^b Medical School of Ribeirao Preto, Infectious Diseases Division, USP, Ribeirão Preto, SP, Brazil

^c Hematology Division, Department of Internal Medicine, Medical School of Ribeirão Preto, USP, Ribeirão Preto, SP, Brazil

ARTICLE INFO

Article history:

Received 15 February 2012

Accepted 23 March 2013

Available online xxx

Keywords:

AIDS

Injected drug use

Anemia

HCV

Mycobacteria

ABSTRACT

HIV patients infected through injected drug use have poorer prognosis than other groups. We evaluated the hematological alterations and rates of co-infections in injected drug use patients with AIDS. Injected drug use patients were younger, predominantly of male gender, and presented lower CD4, total lymphocyte, and platelet counts, but not neutrophil count, than control group. Injected drug use patients had a higher rate of hepatitis C and mycobacteria infection. Furthermore, all injected drug use patients with hemoglobin $<10.0 \text{ g dL}^{-1}$ and lymphocyte $<1000 \mu\text{L}^{-1}$ had CD4 count lower than $100 \mu\text{L}^{-1}$. In conclusion, HIV-infected injected drug use patients constitute a special group of patients, and hemoglobin concentration and lymphocyte count can be used as surrogate markers for disease severity.

© 2012 Elsevier Editora Ltda. All rights reserved.

Introduction

Injected drug use is a risk factor for HIV infection and has been associated with poor outcome.¹ Progression to AIDS and mortality rate are substantially higher in injected drug users (IDU).^{2,3} Many aspects have been associated to this fact: adverse socioeconomic conditions, psychiatric disorders, poor compliance with treatment, and medical restrictions in prescribing antiretroviral therapy, due to concerns of selecting of multidrug-resistant HIV.³ Hepatitis co-infection is commoner

in this population.² HIV infection and AIDS are associated with a wide spectrum of hematological abnormalities.^{4,5} Blood cytopenias can be found in most patients during disease evolution.⁴ Their etiology is multifactorial and include the direct effect of HIV, opportunistic infections and malignancies, or therapies used in the management of AIDS.⁴ Progressive depletion of CD4 lymphocytes is the hallmark of advancing HIV disease and leads to the immunosuppression.⁴ This retrospective cross-sectional study evaluated the hematological particularities of HIV-infected IDU patients and rates of

* Corresponding author at: Rua Tenente Catão Roxo, 2501, Campus da USP, Ribeirao Preto, São Paulo 14051-140, Brazil.

E-mail address: dbrunetta@hotmail.com (D.M. Brunetta).

1413-8670/\$ – see front matter © 2012 Elsevier Editora Ltda. All rights reserved.

<http://dx.doi.org/10.1016/j.bjid.2013.03.010>

Table 1 – Patients' characteristics.

	IDU (n = 104)	Non-IDU (n = 597)	p-Value
Age (years)	40 (27–61)	43 (16–79)	0.001
Male gender (%)	86.5 (90)	57.1 (341)	<0.0001
CD4 < 200 μL^{-1} (%)	37.5 (39)	23.6 (141)	0.0049
Lymphocyte μL^{-1}	1600 (200–4100)	1700 (100–4300)	0.0363
Anemia (%)	44 (46)	36 (175)	NS
Neutrophil μL^{-1}	2500 (400–15,200)	2800 (700–17,500)	NS
Platelet μL^{-1}	213,500 (22,000–550,000)	230,500 (16,000–515,000)	0.0279
Hepatitis C (%)	45.2 (47)	16.6 (99)	<0.0001
Mycobacterium infection (%)	9.6 (10)	3.7 (22)	0.0177

IDU, injection drug user; NS, not significant.
Values expressed as percentage (absolute number) or median (range).

hepatitis and mycobacteria co-infections. Furthermore, we intended to correlate these alterations with CD4 count, and establish a surrogate marker of disease severity combining the results of hemoglobin concentration (Hb) and lymphocyte count.

Materials and methods

We reviewed the data of 701 consecutive HIV-infected patients (≥ 16 years) followed at our institution, of which 14.8% (104) reported injected drug use (Table 1). The parameters recorded were HIV-viral load, Hb, CD4, lymphocyte, neutrophil, and platelet counts. Blood cell and CD4 counts, and HIV viral load quantification were performed as previously described.⁵ Anemia was defined as Hb < 12.0 g dL⁻¹ for women and < 14.0 g dL⁻¹ for men. Statistical analyses were performed using SAS® (version 9.1).

This study was approved by the institution Ethics Committee.

Results

Median ages of IDU and non-IDU groups were 40 (27–61) and 43 (16–79) years, respectively ($p=0.001$). Men comprised 86.5% (90/104) of IDU patients and 57.1% (341/597) of non-IDU patients ($p<0.0001$). CD4 count was lower among IDU than non-IDU patients. CD4 was <200 dL⁻¹ in 37.5% (39/104) and 23.6% (141/597) of IDU and non-IDU patients, respectively ($p=0.0049$). Medians of lymphocyte counts were 1600 μL^{-1} (200–4100 μL^{-1}) and 1700 μL^{-1} (100–4300 μL^{-1}) for IDU and non-IDU groups, respectively ($p=0.0363$). We did not find a significant association between viral load and use of injected drugs ($p=0.2192$). A total of 37.7% (264/701) of the patients had anemia at the moment of analysis, 44% (46/104) among IDU group and 36% (175/432) among non-IDU group ($p=0.15$). Medians of Hb were 11.8 g dL⁻¹ (6.4–15.4 g dL⁻¹) and 12.8 g dL⁻¹ (6.7–15.9 g dL⁻¹) for IDU and non-IDU women, respectively ($p=0.2587$); and 14.3 (6.7–18.7 g dL⁻¹) and 14.4 g dL⁻¹ (6.4–20 g dL⁻¹) for IDU and non-IDU men, respectively ($p=0.6664$). Furthermore, all IDU individuals with Hb < 10 g dL⁻¹ and lymphocyte < 1000 μL^{-1} ($n=10$) presented a CD4 < 100 dL⁻¹ (specificity 100%, sensitivity 29.4%, positive predictive value (PPV) 100% and negative predictive value (NPV) 67.3%). Among the non-IDU group, 81.8%

(18/22) of the individuals with Hb < 10 g dL⁻¹ and lymphocyte < 1000 μL^{-1} presented CD4 < 200 dL⁻¹ (specificity 99.12%, sensitivity 12.7%, PPV 81.8% and NPV 75.7%). Medians of neutrophil counts were 2500 μL^{-1} (400–15,200 μL^{-1}) and 2800 μL^{-1} (700–17,500 μL^{-1}) for IDU and non-IDU groups, respectively ($p=0.1674$). Medians of platelet counts were 213,500 μL^{-1} (22,000–550,000 μL^{-1}) and 230,500 μL^{-1} (16,000–515,000 μL^{-1}) for IDU and non-IDU groups, respectively ($p=0.0279$). After excluding the patients with hepatitis C (HCV), we did not find a significant association between platelet number and injected drug use ($p=0.6868$). A total of 45.2% (47/104) of the IDU group had HCV infection, diagnosed by Elisa and confirmed by PCR, in contrast to 11% among the non-IDU group ($p<0.0001$). Chronic hepatitis B was present in 9.6% of the IDU and 4.8% of the non-IDU ($p=0.0622$) groups. A total of 24% (25/104) of IDU and 16.6% (99/597) of non-IDU groups reported poor adherence to treatment ($p=0.071$). Mycobacteria infection was diagnosed (8 in sputum, 1 in gastric fluid and 1 by lymph node biopsy) in 9.6% (10/104; 6 tuberculosis) among IDU patients and in only 3.7% (22/597; 13 tuberculosis) in the non-IDU ($p=0.0177$) group. We did not find any significant association between injected drug use and other opportunistic infections (data not shown). Mortality was similar in the IDU (1.9%; 2/104) and non-IDU (4.2%; 25/597) groups after 1 year of follow-up ($p=0.4073$).

Discussion

In this study, the IDU group comprised a higher percentage of men than non-IDU patients, a finding that is in accordance with a previous report.³ Moreover, the IDU group was younger, which is also in line with a previous report⁶ but not with another one.³ CD4 cells are the main target of HIV infection and their reduced count is associated with disease progression. We found a lower CD4 count in the IDU group compared with the non-IDU group, despite having similar viral loads. Dronda et al.⁶ have shown long-term poorer recovery of CD4 cells despite successful virological suppression in IDU patients. Anemia is the commonest hematological abnormality in HIV-infected patients and its incidence is associated with disease severity and mortality.^{7,8} Anemia was not higher among IDU than non-IDU patients, in disagreement with data shown by others.⁹ Besides anemia, thrombocytopenia is often observed in HIV-infected patients. Approximately 40%

of HIV patients present thrombocytopenia during the course of their illness.¹⁰ As with other HIV-associated cytopenias, the etiology of thrombocytopenia is multifactorial. Megakaryocytes express CD4¹¹ and CXCR-4¹² and, thereby, are targets for HIV. Besides, expression of viral proteins or altered antigens on the cell membrane make infected megakaryocytes susceptible to immune attack.¹³ Furthermore, HCV infection, commonly found in HIV-infected patients especially among IDU, is a well-known cause of thrombocytopenia.¹⁴ In this study the percentage of HCV among IDU patients was inferior than previously reported.^{6,15} We found a higher frequency of thrombocytopenia in IDU patients, but this finding was observed only in HCV infected patients. Tuberculosis is an endemic infection in Brazil, and its incidence, along with non-tuberculous mycobacterial infections, is increased in HIV patients, especially in the IDU group, a finding that is in accordance with other studies.¹⁶ Furthermore, the proposal of an inexpensive surrogate marker for AIDS severity, such as hemoglobin concentration and lymphocyte count, could be a useful tool for evaluations of AIDS severity in developing countries, where the high prevalence of HIV and low financial resources limit adequate disease monitoring. In conclusion, HIV-infected IDU patients tend to present a more severe disease, as demonstrated by a higher rate of thrombocytopenia and more profound immunosuppression.

Conflict of interest

The authors declare no conflicts of interest.

REFERENCES

1. Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. *Lancet*. 2002;360(9327):119–29.
2. Collaboration ATC. Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients. *J Acquir Immune Defic Syndr*. 2007;46(5):607–15.
3. Qian HZ, Stinnette SE, Rebeiro PF, et al. The relationship between injection and noninjection drug use and HIV disease progression. *J Subst Abuse Treat*. 2011;41(1):14–20.
4. Evans RH, Scadden DT. Haematological aspects of HIV infection. *Baillieres Best Pract Res Clin Haematol*. 2000;13(2):215–30.
5. De Santis GC, Brunetta DM, Vilar FC, et al. Hematological abnormalities in HIV-infected patients. *Int J Infect Dis*. 2011.
6. Dronda F, Zamora J, Moreno S, et al. CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. *AIDS*. 2004;18(16):2210–2.
7. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the multistate adult and adolescent spectrum of HIV disease surveillance project. *Blood*. 1998;91(1):301–8.
8. Nardo M, Brunetta DM, Vilar FC, et al. Hemoglobin concentration increment is associated with a better prognosis in HIV patients with anemia. *Int J Infect Dis*. 2012;16(9):e703.
9. Semba RD, Shah N, Vlahov D. Risk factors and cumulative incidence of anaemia among HIV-infected injection drug users. *Int J STD AIDS*. 2002;13(2):119–23.
10. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ciesielski CA, et al. Surveillance for thrombocytopenia in persons infected with HIV: results from the multistate Adult and Adolescent Spectrum of Disease Project. *J Acquir Immune Defic Syndr Hum Retrovirol*. 1997;14(4):374–9.
11. Kouri YH, Borkowsky W, Nardi M, et al. Human megakaryocytes have a CD4 molecule capable of binding human immunodeficiency virus-1. *Blood*. 1993;81(10):2664–70.
12. Wang JF, Liu ZY, Groopman JE. The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. *Blood*. 1998;92(3):756–64.
13. Louache F, Bettaieb A, Henri A, et al. Infection of megakaryocytes by human immunodeficiency virus in seropositive patients with immune thrombocytopenic purpura. *Blood*. 1991;78(7):1697–705.
14. Louie KS, Micallef JM, Pimenta JM, Forssen UM. Prevalence of thrombocytopenia among patients with chronic hepatitis C: a systematic review. *J Viral Hepat*. 2011;18(1):1–7.
15. Solomon SS, Hawcroft CS, Narasimhan P, et al. Comorbidities among HIV-infected injection drug users in Chennai, India. *Indian J Med Res*. 2008;127(5):447–52.
16. Friedland G. Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. *J Acquir Immune Defic Syndr*. 2010;55 Suppl. 1:S37–42.